VC
Value Add VC
⚡HomePulse⚡Helpful Apps📝Blog🤝Partner
← Pulse/Companies

BlossomHill Therapeutics on Pulse

Biotech

The full thread of our BlossomHill Therapeutics coverage — a running record of every development we've tracked, with the VC take on each.

2
Stories
2
With a headline figure
Aug 3, 2026
Since

Coverage Timeline

newest first
  1. Aug 7, 2026IPOBlossomHill Prices Upsized $150M IPO, Debuts on Nasdaq$150M IPO→
  2. Aug 3, 2026IPOBlossomHill Files for $100M Nasdaq IPO in Cancer Drugs$100M IPO target→

All Coverage

IPO· Aug 7, 2026

BlossomHill Prices Upsized $150M IPO, Debuts on Nasdaq

Illustration for: BlossomHill Prices Upsized $150M IPO, Debuts on Nasdaq
IPO$150M IPO

BlossomHill Prices Upsized $150M IPO, Debuts on Nasdaq

BlossomHill Therapeutics priced an upsized IPO at $16 a share for $150M and began trading on Nasdaq under BLSM, more than 50% above the $100M target Pulse flagged when the company first filed.

Aug 7, 2026FOLLOW-UP
IPO· Aug 3, 2026

BlossomHill Files for $100M Nasdaq IPO in Cancer Drugs

Illustration for: BlossomHill Files for $100M Nasdaq IPO in Cancer Drugs
IPO$100M IPO target

BlossomHill Files for $100M Nasdaq IPO in Cancer Drugs

BlossomHill Therapeutics filed for a $100M Nasdaq IPO under ticker BLSM, adding an oncology-focused biotech with $257M in prior funding to a summer pipeline of clinical-stage listings led by J.P. Morgan, Leerink and Guggenheim.

Aug 3, 2026
@Trace_Cohen·t@nyvp.com